The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma.
Article Details
- CitationCopy to clipboard
Zablocki J, Kalla R, Perry T, Palle V, Varkhedkar V, Xiao D, Piscopio A, Maa T, Gimbel A, Hao J, Chu N, Leung K, Zeng D
The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma.
Bioorg Med Chem Lett. 2005 Feb 1;15(3):609-12.
- PubMed ID
- 15664822 [ View in PubMed]
- Abstract
Adenosine has been suggested to play a role in asthma, possibly via activation of A(2B) adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A(2B) AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A(2B) AdoR antagonist with good selectivity (A(2B) AdoR K(i)=50 nM, selectivity A(1)>200: A(2A)>200: A(3)>167).
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Theophylline Adenosine receptor A1 Ki (nM) 0.6 N/A N/A Details Theophylline Adenosine receptor A2a Ki (nM) 0.6 N/A N/A Details Theophylline Adenosine receptor A2b Ki (nM) 7059 N/A N/A Details